 Raptiva News Alerts
Raptiva, also known as efalizumab, is an injectable psoriasis treatment manufactured by Genentech. Raptiva is designed to treat chronic moderate to severe plaque psoriasis. It works by affecting T-cells and decreases function of the immune system which increases susceptibility to infections.
Raptiva carries a black box warning from the FDA because of the risk of life-threatening infections.
On February 2009, the FDA announced three confirmed and one possible case of progressive multifocal leukoencephalopathy (PML) in long term Raptiva patients. Three of these patients died from the disease.
PML is caused by a virus that affects the central nervous system. It generally occurs in people with weakened immune systems, most often transplant patients, or people suffering from cancer or AIDS. PML can be fatal, with a low chance of survival. People who do overcome PML still suffer permanent neurological damage.
The FDA has advised doctors to monitor patients taking Raptiva for any signs of PML. Symptoms include: unusual weakness, loss of coordination, changes in vision, difficulty speaking, and personality changes.
RAPTIVA LAWYER /
ATTORNEY - FREE CLAIM EVALUATION
If you or a loved one have
suffered from the dangerous side effects of Raptiva and wish to know
if you should file a lawsuit, you should
consider receiving a free legal evaluation from an experienced
Raptiva
lawyer. For a free evaluation of your situation please complete the
following form and a Raptiva attorney will contact you promptly -- free of charge.
RAPTIVA NEWS
Psoriasis Drug Raptiva Tied to Brain Infection
WebMD - Feb 19, 2009
19, 2009 -- The FDA today issued a public health advisory about reports of a rare brain infection in people using the psoriasis drug Raptiva.
US FDA reviews deaths of Genentech Raptiva patients
"WASHINGTON, Feb 19 (Reuters) - U.S. regulators have received three confirmed reports of a serious brain infection in patients treated with Genentech's (DNA.N) psoriasis drug Raptiva, the Food and Drug Administration said on Thursday.
New Warning on Genentech’s Raptiva; What Is PML, Anyway?
"The FDA said today that patients taking the Genentech drug Raptiva are at risk of developing a potentially fatal condition known as PML, or progressive multifocal leukoencephalopathy.
Everyday Poisonings, Psoriasis Drug Deaths and Wider Use of Statins
"The Food and Drug Administration is investigating a possible link between the psoriasis drug efalizumab, sold under the brand name Raptiva, and three, or possibly four, deaths from a rare degenerative condition of the brain, progressive multifocal leukoencephalopathy, reports the Los Angeles Times health blog. The illness is characterized by mental deterioration, vision loss and other neurological symptoms, and most often affects people with impaired immune systems.
Contact us for
Raptiva Lawyer Representation in Los Angeles, CA; Baltimore, MD;
Boston, MA, St. Paul, MN; St. Louis, MO; New York, NY; Raleigh,
Greensboro, Charlotte, NC; Scranton Wilkes-Barre Harrisburg
Philadelphia, PA; Dallas, TX and
Los Angeles, CA; Baltimore, MD; Boston, MA, St.
Paul, MN; St. Louis, MO; New York, NY; Raleigh, Greensboro,
Charlotte, NC; Scranton Wilkes-Barre Harrisburg Philadelphia, PA;
Dallas, TX and Alabama | Arkansas | Arizona | California | Colorado
| Connecticut | DC Washington | Delaware | Florida | Georgia |
Hawaii | Iowa | Idaho | Illinois | Indiana | Kansas | Kentucky |
Louisiana | Massachusetts | Maryland | Maine | Michigan | Minnesota
| Missouri | Mississippi | Montana | North Carolina | North Dakota |
Nebraska | New Hampshire | New Jersey | New Mexico | Nevada | New
York | Ohio | Oklahoma | Oregon | Pennsylvania | Rhode Island |
South Carolina | South Dakota | Tennessee | Texas | Utah | Virginia
| Vermont | Washington | Wisconsin | West Virginia | Wyoming |
Canada | International
Top of Page
|
